论文部分内容阅读
目的:探讨米非司酮治疗围绝经期功能失调性子宫出血临床效果。方法:选择2003年9月~2006年1月在东莞市人民医院确诊为围绝经期功血的患者57例,每晚睡前空腹口服米非司酮12.5 mg,每天一次,连续6个月,于治疗前及治疗3个月、6个月分别检测性激素6项、肝肾功能及血常规,观察月经情况,B超监测子宫内膜厚度。结果:治疗期间所有患者均闭经,血促卵泡生成素(FSH)、促黄体生成素(LH)、泌乳素(PRL)、睾酮(T)变化不明显,血孕酮(P)和雌二醇(E2)水平明显(P<0.01);子宫内膜变薄,由用药前(1.0±0.3)cm至用药后(0.4±0.2)cm(P<0.05);血红蛋白均有不同程度的提高,贫血得到改善。结论:米非司酮治疗围绝经期功能失调性子宫出血是一种安全有效的治疗方法,值得临床推广。
Objective: To investigate the clinical effect of mifepristone in treating peri-menopausal dysfunctional uterine bleeding. Methods: From September 2003 to January 2006 in Dongguan City People’s Hospital diagnosed as perimenopausal dysfunctional uterine bleeding in 57 patients, fasting every night before taking oral mifepristone 12.5 mg once a day for 6 months, Pretreatment and treatment of 3 months, 6 months were detected sex hormone 6, liver and kidney function and blood routine observation of menstruation, B-monitoring of endometrial thickness. Results: All the patients had amenorrhea, no change of FSH, LH, PRL and T during the treatment period. The blood progesterone (P) and estradiol (1.0 ± 0.3) cm before treatment (0.4 ± 0.2) cm (P <0.05). The levels of hemoglobin were increased to some extent, and the levels of serum E2 were significantly higher (P <0.01) Improved. Conclusion: Mifepristone is a safe and effective treatment for dysfunctional uterine bleeding in perimenopausal period, which is worthy of clinical promotion.